Likelihood of Approval and Phase Transition Success Rate Model – Zimberelimab in Pancreatic Ductal Adenocarcinoma
Powered by ![]()
Unlock hidden opportunities in the LoA industry
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model – Zimberelimab in Pancreatic Ductal Adenocarcinoma report and make more profitable business decisions.
This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.


Zimberelimab in Pancreatic Ductal Adenocarcinoma Drug Details:
Zimberelimab (Sepalizumab) is a human monoclonal monospecific antibody that belongs to a class of immuno-oncology agents. It is formulated as injectable solution for intravenous drip route of administration. Zimberelimab is indicated for the treatment of recurrent or refractory classical Hodgkin’s lymphoma (cHL). GLS-010 (AB-122) is under development for the treatment of metastatic cervical cancer, metastatic castrate resistant prostate cancer (mCRPC), locally advanced/metastatic pancreatic cancer, glioblastoma multiforme (GBM), recurrent glioblastoma multiforme (GBM), rectal cancer, gastric cancer, esophageal squamous cell carcinoma, head and neck squamous cell carcinoma, oral cavity (mouth) cancer, oropharyngeal cancer, laryngeal cancer, hypopharyngeal cancer, squamous non-small cell lung cancer, extrahepatic bile duct cancer, esophageal cancer, non-small-cell lung cancer, urothelial cancer, colorectal cancer (CRC), pancreatic ductal adenocarcinoma, liver cancer, nasopharyngeal cancer, peripheral T lymphoma, natural killer cell lymphoma, bile duct cancer, metastatic melanoma, cervical cancer, multiple myeloma (Kahler disease), non-Hodgkin lymphoma, diffuse large B-cell lymphoma, adenocarcinoma of the gastroesophageal junction, hepatocellular cancer, bile duct cancer (including intrahepatic cholangiocarcinoma, extrahepatic cholangiocarcinoma and gall bladder cancer. The drug candidate is a humanized monoclonal antibody administered through intravenous route. It acts by targeting PD-1 and is developed based on OmniRat technology platform. The drug candidate is under development for the treatment of breast cancer, ovarian cancer, gastroesophageal cancer, squamous cell carcinoma of the head and neck, Merkel cell carcinoma, melanoma, bladder cancer, endometrial cancer and renal cell carcinoma.
Report Coverage
The data is segmented by drug name per indication and shows the current likelihood of approval for the drug compared to the indication benchmark and the industry benchmark.
The Likelihood of Approval data is updated regularly based on events that take place which impact the clinical development process and regulatory considerations. GlobalData’s proprietary machine learning models consider these events in real time, to produce quantitative changes to the LOA and PTSR along with qualitative reasoning why the likelihood of approval has changed.
| Quick View – Zimberelimab LOA Data | |||||
| Report Segments |
|
||||
| Drug Name |
|
||||
| Administration Pathway |
|
||||
| Therapeutic Areas |
|
||||
| Key Manufacturers |
|
||||
| Drug Development Status |
|
||||
Reasons to Buy
- Precise Likelihood of Approval and Phase Transition Success Rates: Our machine learning and proprietary models provide accurate predictions, helping you gauge the potential success of a drug in the regulatory process.
- Competitive Strategy Planning: Access information on LOA and PTSR for competitors’ drugs, allowing you to plan your clinical development, commercialisation and marketing strategies
- Event-driven Updates: Track event-driven changes in LOA and PTSR benchmarked against indication LOA/PTSR. Get the latest insights to adapt your strategies promptly!
- Well-informed Investment Decisions: This data helps you navigate the dynamic landscape of drug development and regulatory considerations.
Scope
- Drug Details: Drug name, Drug type, Intervention type
- Administration Pathway
- Therapeutic Areas
- Key Manufacturers
- Drug Development Status
This is an on-demand report that will be delivered upon request. The report will be delivered within 2 business days of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on data availability and relevance.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Related reports
View more Pharmaceuticals reports